NO20082406L - Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen - Google Patents

Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen

Info

Publication number
NO20082406L
NO20082406L NO20082406A NO20082406A NO20082406L NO 20082406 L NO20082406 L NO 20082406L NO 20082406 A NO20082406 A NO 20082406A NO 20082406 A NO20082406 A NO 20082406A NO 20082406 L NO20082406 L NO 20082406L
Authority
NO
Norway
Prior art keywords
human platelet
monoclonal antibody
recognizes
platelet alloantigen
antibody
Prior art date
Application number
NO20082406A
Other languages
English (en)
Norwegian (no)
Inventor
Dominique Rigal
Jean Jacques Pin
Yves Merieux
Original Assignee
Diagnostische Forsch Stiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostische Forsch Stiftung filed Critical Diagnostische Forsch Stiftung
Publication of NO20082406L publication Critical patent/NO20082406L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20082406A 2007-06-22 2008-05-28 Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen NO20082406L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07012282A EP2006304A1 (fr) 2007-06-22 2007-06-22 Anticorps monoclonal anti-HPA-5b

Publications (1)

Publication Number Publication Date
NO20082406L true NO20082406L (no) 2008-12-23

Family

ID=38510463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082406A NO20082406L (no) 2007-06-22 2008-05-28 Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen

Country Status (5)

Country Link
US (1) US8080242B2 (fr)
EP (1) EP2006304A1 (fr)
JP (1) JP2009013175A (fr)
AU (1) AU2008202154A1 (fr)
NO (1) NO20082406L (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2796880B1 (fr) * 2013-04-26 2016-10-26 Davos Diagnostics AG Typage allo-antigène plaquettaire et tests d'anticorps plaquettaire
RS59704B1 (sr) 2014-03-31 2020-01-31 Univ I Tromsoe Norges Arktiske Univ Antitela protiv hpa-1a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516634A (en) * 1993-06-30 1996-05-14 Newman; Peter J. Molecular basis of the human platelet bra/brb alloantigen system and applications thereof
KR100308764B1 (ko) * 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
US5955266A (en) * 1996-04-01 1999-09-21 The Johns Hopkins University School Of Medicine Use of platelet polymorphism P1A2 to diagnose risk of thrombotic disease
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US20030027207A1 (en) * 2000-02-29 2003-02-06 Filpula David Ray Anti-platelet binding proteins and polymer conjugates containing the same

Also Published As

Publication number Publication date
JP2009013175A (ja) 2009-01-22
AU2008202154A1 (en) 2008-12-11
US20090117128A1 (en) 2009-05-07
EP2006304A1 (fr) 2008-12-24
US8080242B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
PA8850201A1 (es) Combinaciones antitumorales que contienen anticuerpos
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
NO20074238L (no) Fiksert dosering av HER-antistoffer
NO20084878L (no) Humanisert C-kit antistoff
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
PA8849901A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y la citarabina
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
UY30776A1 (es) Anticuerpos cd44
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
NO20080246L (no) Anti-IGF1R-antistofformuleringer
NO20075845L (no) Fremgangsmate for behandling av inflammatorisk tarmsykdom (IBD) med et anti-CD20-antistoff
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
PA8850101A1 (es) Combinaciones antitumorales que contienen anticuerpos
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MEP35408A (en) Tweak binding antibodies
HN2006015949A (es) Anticuerpos de p-caderina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application